ArticleClinical, cosmetic and investigational dermatology2026
Optimizing Abrocitinib Use for Atopic Dermatitis in India: Expert Recommendations for Patient Selection, Dosing, and Long‑Term Remission.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder which significantly impairs quality of life due to persistent pruritus, sleep disturbance, and recurrent flares. Conventional systemic therapies, such as cyclosporine and methotrexate, often provide inadequate itch and disease control, with limited safety and poor long-term tolerability. The introduction of targeted small-molecule therapies, particularly Janus kinase (JAK) inhibitors, has substantially transformed AD management by enabling rapid itch relief and sustained clinical improvements. Abrocitinib, an oral selective JAK1 inhibitor, has demonstrated rapid and clinically meaningful reduction in pruritus, improvement in skin lesions, and a favorable benefit-risk profile in pivotal clinical trials. However, guidance regarding its optimal real-world use in Indian patients remains limited. This expert recommendation aims to provide practical, experience-based recommendations for the initiation, dosing, monitoring, and long-term management of abrocitinib in patients with moderate-to-severe AD in India. A multistep approach was employed, including a targeted literature review conducted between September and November 2025, a nationwide survey of 36 experienced dermatologists, and two virtual expert panel meetings involving 10 senior clinicians. Experts have identified abrocitinib as a valuable systemic option, particularly for patients with pruritus‑dominant disease, head and neck involvement, hand eczema, elderly patients with comorbidities, and those inadequately controlled with biologics or other systemic agents. Baseline assessment of hematologic, hepatic, renal, lipid, infectious, cardiovascular, and thrombotic risks was emphasized, with follow-up monitoring recommended at four weeks and following dose modifications. An induction dose of 200 mg once daily was preferred for most patients, with 100 mg reserved for the selected populations. Strategies for maintenance, dose tapering, and treatment transitions were also discussed. Overall, these expert recommendations provide practical real-world guidance supporting the individualized, safe, and effective use of abrocitinib in the Indian clinical setting, while emphasizing the importance of structured monitoring and long-term treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.